Pictet Asset Management Holding SA Purchases 49,901 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Pictet Asset Management Holding SA increased its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 16.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 347,854 shares of the company's stock after acquiring an additional 49,901 shares during the quarter. Pictet Asset Management Holding SA owned approximately 0.28% of Apellis Pharmaceuticals worth $11,100,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Norges Bank purchased a new stake in shares of Apellis Pharmaceuticals during the fourth quarter valued at approximately $34,662,000. EFG Asset Management North America Corp. grew its stake in Apellis Pharmaceuticals by 30.5% in the 4th quarter. EFG Asset Management North America Corp. now owns 43,157 shares of the company's stock valued at $1,378,000 after purchasing an additional 10,087 shares during the period. Vanguard Group Inc. increased its position in shares of Apellis Pharmaceuticals by 2.3% during the 4th quarter. Vanguard Group Inc. now owns 10,046,025 shares of the company's stock valued at $320,569,000 after purchasing an additional 230,450 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of Apellis Pharmaceuticals during the 4th quarter worth $504,000. Finally, Teacher Retirement System of Texas boosted its holdings in shares of Apellis Pharmaceuticals by 9.4% in the 4th quarter. Teacher Retirement System of Texas now owns 21,649 shares of the company's stock worth $691,000 after buying an additional 1,864 shares during the last quarter. 96.29% of the stock is owned by institutional investors.

Remove Ads

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on APLS. Scotiabank raised their price objective on shares of Apellis Pharmaceuticals from $30.00 to $31.00 and gave the stock a "sector perform" rating in a report on Wednesday, April 2nd. HC Wainwright reaffirmed a "buy" rating and issued a $57.00 price target on shares of Apellis Pharmaceuticals in a report on Monday, March 3rd. Wedbush dropped their price objective on Apellis Pharmaceuticals from $30.00 to $29.00 and set a "neutral" rating on the stock in a research note on Monday, March 3rd. The Goldman Sachs Group decreased their target price on Apellis Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a research report on Monday, March 3rd. Finally, Royal Bank of Canada dropped their price objective on shares of Apellis Pharmaceuticals from $26.00 to $25.00 and set a "sector perform" rating on the stock in a report on Monday, March 3rd. Eight equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $45.59.

Insider Transactions at Apellis Pharmaceuticals

In other news, General Counsel David O. Watson sold 5,569 shares of the stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $25.10, for a total transaction of $139,781.90. Following the sale, the general counsel now owns 138,730 shares in the company, valued at $3,482,123. This represents a 3.86 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Cedric Francois sold 6,247 shares of the business's stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $28.70, for a total transaction of $179,288.90. Following the completion of the transaction, the chief executive officer now owns 307,415 shares of the company's stock, valued at approximately $8,822,810.50. The trade was a 1.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 63,238 shares of company stock valued at $1,857,510 in the last ninety days. 6.80% of the stock is currently owned by corporate insiders.

Apellis Pharmaceuticals Stock Down 0.9 %

Apellis Pharmaceuticals stock traded down $0.17 on Monday, hitting $19.80. 3,082,473 shares of the stock traded hands, compared to its average volume of 2,101,106. The business's fifty day simple moving average is $26.02 and its 200 day simple moving average is $28.84. The firm has a market cap of $2.49 billion, a P/E ratio of -9.75 and a beta of 0.85. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. Apellis Pharmaceuticals, Inc. has a 1 year low of $18.21 and a 1 year high of $57.85.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last posted its quarterly earnings data on Friday, February 28th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.08. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business had revenue of $212.50 million for the quarter, compared to analyst estimates of $197.92 million. During the same quarter in the previous year, the firm posted ($0.73) earnings per share. Apellis Pharmaceuticals's quarterly revenue was up 45.2% on a year-over-year basis. As a group, sell-side analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).